Amgen, Sandoz trial over Enbrel patents likely delayed—and a biosimilar could be, too
admin 2nd April 2018 Uncategorised 0A patent fight has already delayed Sandoz’ biosimilar version of Amgen’s anti-inflammatory blockbuster Enbrel. And now, it looks as if Sandoz will have to wait a little longer for a clear shot at the launch.
More: Amgen, Sandoz trial over Enbrel patents likely delayed—and a biosimilar could be, too
Source: fierce